Director LANGE LOUIS G Sells 28,186 Shares of Newamsterdam Pharma Amid Quiet Rally, Balancing Gains and Hedging Strategy

Insider Selling Amid a Quiet Rally

On March 6, 2026, director LANGE LOUIS G sold 28,186 ordinary shares of Newamsterdam Pharma Co NV at an average price of $29.41—just below the market close of $29.86. The sale, conducted through the LGLange III Trust, was executed in a series of trades ranging from $29.03 to $29.68, indicating a deliberate, orderly divestiture rather than a fire‑sale. While the transaction size is modest relative to the company’s market cap of $3.5 billion, it is notable because it follows a period of significant insider buying by the same individual, who purchased 54,979 shares on March 9 at $11.50, nearly tripling his stake.

Implications for Investors

The timing of the sale coincides with a 2.85 % weekly rally and a 33.86 % year‑to‑date gain, yet the price remains below the 52‑week high of $42.0. The modest outflow may signal confidence that the stock is still undervalued, especially given the company’s negative earnings and high valuation multiples. However, the sale could also be interpreted as a liquidity event for LANGE LOUIS G, potentially raising concerns about a future loss of support from a key insider. For long‑term investors, the transaction may be a neutral signal: the director remains an active participant in the company’s capital structure, as evidenced by his recent purchases.

LANGE LOUIS G – A Transaction Profile

LANGE LOUIS G’s trading history over the last two months shows a pattern of alternating purchases and sales, often involving option contracts. In January he bought 15,300 options and 3,400 shares, and by early March he had sold 44,619 shares (and the corresponding warrants) at $11.50, then repurchased 54,979 shares at the same price. This suggests a strategy of capturing upside during low‑price periods while maintaining a long position that can be liquidated when the market improves. His most recent sale at $29.41 aligns with this cycle: a partial exit during a sustained uptrend, preserving capital for future upside or for other investments.

Company‑Wide Insider Activity

Newamsterdam’s chief scientific officer, Kastelein, and CEO Davidson have also been active, buying and selling large blocks of shares in the same period. The cumulative insider buying totals over 400,000 shares, while sales amount to roughly 200,000 shares. The net insider net position remains positive, indicating that management believes in the company’s long‑term prospects. The recent sales by LANGE LOUIS G are therefore an outlier rather than a systemic shift in sentiment.

Outlook

With a market cap of $3.5 billion and a current P/E of –17.4, Newamsterdam Pharma remains a speculative play. The insider sale on March 6, coupled with the broader context of active buying, suggests that insiders are hedging rather than abandoning the stock. For investors, the key takeaway is that insider transactions are part of a broader strategy of capital allocation, not an immediate red flag. Monitoring future filings for shifts in net insider positions and any clinical milestones will remain essential for gauging the company’s trajectory.